RU2018136076A - Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения - Google Patents

Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения Download PDF

Info

Publication number
RU2018136076A
RU2018136076A RU2018136076A RU2018136076A RU2018136076A RU 2018136076 A RU2018136076 A RU 2018136076A RU 2018136076 A RU2018136076 A RU 2018136076A RU 2018136076 A RU2018136076 A RU 2018136076A RU 2018136076 A RU2018136076 A RU 2018136076A
Authority
RU
Russia
Prior art keywords
trastuzumab
mcc
docetaxel
administered
paragraphs
Prior art date
Application number
RU2018136076A
Other languages
English (en)
Other versions
RU2018136076A3 (ru
RU2781195C2 (ru
Inventor
Линн БЕРРИ
Гейл Льюис ФИЛЛИПС
Марк Кс. СЛИВКОВСКИ
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40858064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018136076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2018136076A publication Critical patent/RU2018136076A/ru
Publication of RU2018136076A3 publication Critical patent/RU2018136076A3/ru
Application granted granted Critical
Publication of RU2781195C2 publication Critical patent/RU2781195C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)

Claims (15)

1. Способ лечения гиперпролиферативного нарушения, включающий введение терапевтической комбинации в виде комбинированной композиции или поочередно млекопитающему, где терапевтическая комбинация содержит трастузумаб-МСС-DM1 и доцетаксел.
2. Способ по п. 1, где трастузумаб-МСС-DM1 и доцетаксел вводят в виде комбинированной композиции.
3. Способ по п. 1, где трастузумаб-МСС-DM1 и доцетаксел вводят поочередно.
4. Способ по п. 3, где млекопитающему вводят доцетаксел и затем впоследствии вводят трастузумаб-MCC-DM1.
5. Способ по любому из пп. 1-4, где терапевтическую комбинацию вводят человеку с гиперпролиферативным нарушением с интервалами три недели.
6. Способ по п. 3, где трастузумаб-MCC-DM1 вводят человеку с гиперпролиферативным нарушением с интервалами от одной недели до трех недель.
7. Способ по п. 3, где трастузумаб-MCC-DM1 вводят не чаще, чем каждые 3 недели при дозировке 2,4, 3,0, или 3,6 мг/кг внутривенно.
8. Способ по любому из пп. 1-7, где количество трастузумаба-MCC-DM1 и количество доцетаксела составляет для каждого от 1 мг до 1000 мг, и количество трастузумаба-MCC-DM1 и количество доцетаксела находятся в соотношении от 1:10 до 10:1 по массе.
9. Способ по любому из пп. 1-8, где гиперпролиферативное нарушение представляет собой злокачественную опухоль.
10. Способ по любому из пп. 1-8, где гиперпролиферативное нарушение представляет собой злокачественную опухоль, экспрессирующую ErbB2.
11. Способ по п. 10, где млекопитающим является пациент с положительных реакций на HER2.
12. Способ по п. 11, где пациент с положительных реакций на HER2 получал терапию трастузумабом или лапатинибом.
13. Способ по любому из пп. 1-12, где введение терапевтической комбинации приводит к синергетическому результату.
14. Фармацевтическая композиция, содержащая трастузумаб-МСС-DM1 и доцетаксел и один или несколько фармацевтически приемлемых носителей, регуляторов сыпучести, разбавителей или наполнителей.
15. Фармацевтическая композиция по п.14, содержащая фармацевтически приемлемый регулятор сыпучести, выбранный из диоксида кремния, порошкообразной целлюлозы, микрокристаллической целлюлозы, стеаратов металлов, алюмосиликата натрия, бензоата натрия, карбоната кальция, силиката кальция, кукурузного крахмала, карбоната магния, не содержащего примеси асбеста талька, стеаровета C, крахмала, крахмала 1500, лаурилсульфата магния, оксида магния и их комбинаций.
RU2018136076A 2008-03-18 2018-10-12 Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения RU2781195C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3741008P 2008-03-18 2008-03-18
US61/037,410 2008-03-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013147514A Division RU2671489C2 (ru) 2008-03-18 2013-10-24 Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022125791A Division RU2022125791A (ru) 2008-03-18 2022-10-03 Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения

Publications (3)

Publication Number Publication Date
RU2018136076A true RU2018136076A (ru) 2020-04-13
RU2018136076A3 RU2018136076A3 (ru) 2021-10-25
RU2781195C2 RU2781195C2 (ru) 2022-10-07

Family

ID=

Also Published As

Publication number Publication date
MY166445A (en) 2018-06-27
PH12014502133B1 (en) 2015-06-29
SI2644194T1 (sl) 2017-08-31
CA2990929C (en) 2022-04-12
CN102036660A (zh) 2011-04-27
JP2020147570A (ja) 2020-09-17
MY188477A (en) 2021-12-13
KR20180035923A (ko) 2018-04-06
PL3269366T3 (pl) 2020-07-27
US20230201210A1 (en) 2023-06-29
TWI449536B (zh) 2014-08-21
IL234065A0 (en) 2014-09-30
CA2716592A1 (en) 2009-09-24
KR20150115951A (ko) 2015-10-14
EP2644204A2 (en) 2013-10-02
SG10201401942PA (en) 2014-08-28
JP5656823B2 (ja) 2015-01-21
SG10201401941RA (en) 2014-07-30
JP2014132009A (ja) 2014-07-17
RU2018136076A3 (ru) 2021-10-25
HUE035184T2 (en) 2018-05-02
WO2009117277A2 (en) 2009-09-24
IL274393B (en) 2022-09-01
TW200942261A (en) 2009-10-16
EP2644204B1 (en) 2017-04-19
CR20180483A (es) 2018-12-05
US8663643B2 (en) 2014-03-04
TW201511771A (zh) 2015-04-01
KR101751065B1 (ko) 2017-06-26
EP2254571B1 (en) 2015-07-01
EP3692988A3 (en) 2020-10-14
EP2644204A3 (en) 2014-02-12
ES2773510T3 (es) 2020-07-13
CR11678A (es) 2010-12-13
PH12019501792A1 (en) 2021-03-22
CN104888232B (zh) 2019-05-10
KR20160125535A (ko) 2016-10-31
KR20100129318A (ko) 2010-12-08
NZ709293A (en) 2017-01-27
NZ587706A (en) 2012-12-21
TWI527593B (zh) 2016-04-01
EP3269366B1 (en) 2020-01-15
MX2022000579A (es) 2022-02-10
EP2644194A3 (en) 2014-01-01
MY184496A (en) 2021-04-01
PH12014502134A1 (en) 2015-06-29
CN104873980B (zh) 2019-07-19
RU2010142390A (ru) 2012-04-27
JP6016825B2 (ja) 2016-10-26
CN104888231B (zh) 2019-05-17
EP2644194B1 (en) 2017-04-19
CA2990929A1 (en) 2009-09-24
RU2510272C2 (ru) 2014-03-27
JP2016040273A (ja) 2016-03-24
JP6705788B2 (ja) 2020-06-03
MA32223B1 (fr) 2011-04-01
US20170136026A1 (en) 2017-05-18
CN102036660B (zh) 2015-05-06
CN110251670A (zh) 2019-09-20
EP3269366A3 (en) 2018-04-04
IL295098A (en) 2022-09-01
PL2644194T3 (pl) 2017-09-29
KR101772304B1 (ko) 2017-08-28
BRPI0906181A2 (pt) 2015-06-30
WO2009117277A3 (en) 2010-04-29
IL234064A0 (en) 2014-09-30
MY201555A (en) 2024-02-28
CN104888232A (zh) 2015-09-09
KR20230054478A (ko) 2023-04-24
JP2012500180A (ja) 2012-01-05
TWI574698B (zh) 2017-03-21
ES2545977T3 (es) 2015-09-17
HUE035182T2 (hu) 2018-05-02
EP3269366A2 (en) 2018-01-17
NZ621433A (en) 2015-10-30
JP6388859B2 (ja) 2018-09-12
MX353429B (es) 2018-01-12
EP2644194A2 (en) 2013-10-02
KR20210131473A (ko) 2021-11-02
PL2644204T3 (pl) 2017-09-29
HUE025507T2 (en) 2016-02-29
CN110251670B (zh) 2023-11-14
EP3692988A2 (en) 2020-08-12
ES2629405T3 (es) 2017-08-09
US20190374547A1 (en) 2019-12-12
NZ602675A (en) 2014-03-28
HK1147444A1 (en) 2011-08-12
SI2644204T1 (sl) 2017-08-31
UA127472C2 (uk) 2023-09-06
TWI675668B (zh) 2019-11-01
IL207894A0 (en) 2010-12-30
RU2013147514A (ru) 2015-04-27
PH12014502133A1 (en) 2015-06-29
PH12014502134B1 (en) 2015-06-29
IL234064B (en) 2020-05-31
KR20190077616A (ko) 2019-07-03
SI2254571T1 (sl) 2015-10-30
DK2644194T3 (en) 2017-07-03
CL2009000559A1 (es) 2010-10-15
KR102449659B1 (ko) 2022-09-29
US20140140993A1 (en) 2014-05-22
DK2644204T3 (en) 2017-07-03
CA3146422A1 (en) 2009-09-24
EP2638907A2 (en) 2013-09-18
EP2638907A3 (en) 2014-05-14
SG10202104314YA (en) 2021-06-29
IL274393A (en) 2020-06-30
CN104873980A (zh) 2015-09-02
AU2009225877A1 (en) 2009-09-24
IL234066A0 (en) 2014-09-30
ES2629067T3 (es) 2017-08-07
MY166446A (en) 2018-06-27
AU2009225877B2 (en) 2014-11-20
US20120107302A1 (en) 2012-05-03
RU2671489C2 (ru) 2018-11-01
UA108832C2 (uk) 2015-06-25
DK2254571T3 (en) 2015-09-28
JP2018052946A (ja) 2018-04-05
KR20200113026A (ko) 2020-10-05
CA2716592C (en) 2018-02-27
TW201611846A (en) 2016-04-01
PH12014502135B1 (en) 2015-06-29
MX2010010168A (es) 2010-10-04
PL2254571T3 (pl) 2015-11-30
EP2254571A2 (en) 2010-12-01
TW201722475A (zh) 2017-07-01
IL234065B (en) 2018-06-28
AR070865A1 (es) 2010-05-12
IL207894A (en) 2015-09-24
CN104888231A (zh) 2015-09-09
ZA201006186B (en) 2011-11-30
PH12014502135A1 (en) 2015-06-29
IL259499A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
RU2013147514A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
JP2014509659A5 (ru)
WO2020181214A1 (en) Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment
JP2016528162A5 (ru)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2014512355A5 (ru)
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
EP2425830A1 (en) Synergistic drug combination for the treatment of cancer
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
JPWO2020160527A5 (ru)
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
RU2017136693A (ru) Способы поддержания, лечения или улучшения когнитивной функции
JP2019151621A (ja) Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
RU2014128528A (ru) Лечение диабета I и II типа
RU2018130601A (ru) Галеновые композиции органических соединений